Percutaneous mitral valve repair in patients with secondary mitral regurgitation and advanced heart failure

Abstract

Advanced heart failure (HF) prevalence is increasing and ranges between 1% and 10% of the overall HF population, due to the growing number of patients with HF and their better treatment and survival in the last 20 years. The best treatment for these patients is represented by heart transplantation, which, unfortunately, is only available for a minority of them. A significant portion of patients with advanced HF has concomitant severe mitral regurgitation, which acts as a driving force in inducing and maintaining this end-stage condition in a vicious cycle. Percutaneous mitral valve repair with MitraClip is a treatment option to stop this vicious cycle, providing safer outcomes and clinical benefits in some of these patients. Preliminary clinical observations show a possible selective role for percutaneous mitral valve treatment with MitraClip as a bridge to transplantation, candidacy or recovery. Further evidence will be necessary to confirm these preliminary data and support this new treatment framework of patients with advanced HF.

Keywords

Mitral regurgitation / secondary mitral regurgitation / percutaneous mitral valve repair / advanced heart failure / heart transplantation / bridge therapy

References

[1] Iung B.Epidemiology of valvular heart disease in the adult..Nat Rev Cardiol2011;8:162-72

[2] Sannino A,Schiattarella GG,Esposito G.Survival and cardiovascular outcomes of patients with secondary mitral regurgitation: a systematic review and meta-analysis..JAMA Cardiol2017;2:1130-9 PMCID:PMC5710448

[3] Godino C,Taramasso M,Russo M.Two-year cardiac mortality after MitraClip treatment of functional mitral regurgitation in ischemic and non-ischemic dilated cardiomyopathy..Int J Cardiol2018;269:33-9

[4] Goliasch G,Pavo N,Wurm R.Refining the prognostic impact of functional mitral regurgitation in chronic heart failure..Eur Heart J2018;39:39-46

[5] Adamo M,Giannini C,Liga R.Left ventricular reverse remodelling predicts long-term outcomes in patients with functional mitral regurgitation undergoing MitraClip therapy: results from a multicentre registry..Eur J Heart Fail2018;21:196-204

[6] Godino C,Cera M,Fragasso G.Impact and evolution of right ventricular dysfunction after successful MitraClip implantation in patients with functional mitral regurgitation..IJC Hear Vasc2016;11:90-8 PMCID:PMC5441334

[7] Godino C,Sisinni A,Saia F.MitraClip treatment of secondary mitral regurgitation in heart failure with reduced ejection fraction: lessons and implications from trials and registries..Structural Heart2020;1-7

[8] Stone GW,Abraham WT,Lim DS.Transcatheter mitral-valve repair in patients with heart failure..N Engl J Med2018;379:2307-18

[9] Obadia JF,Leurent G,Bonnet G.Percutaneous repair or medical treatment for secondary mitral regurgitation..N Engl J Med2018;379:2297-306

[10] Crespo-Leiro MG,Lund LH,Costanzo MR.Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology..Eur J Heart Fail2018;20:1505-35

[11] Baumwol J.“I Need Help” - A mnemonic to aid timely referral in advanced heart failure..J Hear Lung Transplant2017;36:593-4

[12] Eurotransplant International Foundation. Annual Report 2018. Vol. 4. AIMS Mathematics; 2019. pp. 166-9. Available from: https://www.eurotransplant.org/wp-content/uploads/2020/05/ET_Jaarverslag_2018.pdf [Last accessed on 13 Jul 2020]

[13] Starling RC,Horstmanshof DA,Stehlik J.Risk assessment and comparative effectiveness of left ventricular assist device and medical management in ambulatory heart failure patients: the ROADMAP study 2-year results..JACC Hear Fail2017;5:518-27

[14] Mehra MR,Hannan MM,Uber PA.The 2016 international society for heart lung transplantation listing criteria for heart transplantation: a 10-year update..J Hear Lung Transplant2016;35:1-23

[15] Patel JB,Barnes ME,Daly RC.Mitral regurgitation in patients with advanced systolic heart failure..J Card Fail2004;10:285-91

[16] Lancellotti P.Progression of secondary mitral regurgitation: From heart failure to valvular heart failure..Eur Heart J Cardiovasc Imaging2018;19:613-4

[17] Packer M.New evidence supporting a novel conceptual framework for distinguishing proportionate and disproportionate functional mitral regurgitation..JAMA Cardiol2020;

[18] Packer M.Neurohormonal and transcatheter repair strategies for proportionate and disproportionate functional mitral regurgitation in heart failure..JACC Heart Fail2019;7:518-21

[19] Packer M.Contrasting effects of pharmacological, procedural, and surgical interventions on proportionate and disproportionate functional mitral regurgitation in chronic heart Failure..Circulation2019;140:779-89

[20] Grayburn PA,Packer M.Proportionate and disproportionate functional mitral regurgitation: a new conceptual framework that reconciles the results of the MITRA-FR and COAPT trials..JACC Cardiovasc Imaging2019;12:353-62

[21] Food and Drug Administration. Summary of safety and effectiveness (SSED): MitraClip NT Clip Delivery System, MitraClip NTR/XTR Clip Delivery System. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf10/P100009S028B.pdf [Last accessed on 10 Jul 2020]

[22] Adamo M,Gavazzoni M,Lupi L.Impact of disproportionate secondary mitral regurgitation in patients undergoing edge-to-edge percutaneous mitral valve repair..EuroIntervention2020;

[23] Bonow RO,Adams DH,Bavaria JE.2020 focused update of the 2017 ACC expert consensus decision pathway on the management of mitral regurgitation: a report of the American college of cardiology solution set oversight committee..J Am Coll Cardiol2020;75:2236-70

[24] Franzen O,Baldus S,Schillinger W.MitraClip^® therapy in patients with end-stage systolic heart failure..Eur J Heart Fail2011;13:569-76

[25] Garatti A,Bandera F,Menicanti L.Mitraclip procedure as a bridge therapy in a patient with heart failure listed for heart transplantation..Ann Thorac Surg2015;99:1796-9

[26] Sankar NM,Anantharaman R.MitraClip and mitral annuloplasty device as a bridge to transplantation..Asian Cardiovasc Thorac Ann2018;26:57-9

[27] Alfieri O,De Bonis M,Torracca L.The double-orifice technique in mitral valve repair: a simple solution for complex problems..J Thorac Cardiovasc Surg2001;122:674-81

[28] Berardini A,Saia F,Previtali M.Percutaneous mitral valve repair: The last chance for symptoms improvement in advanced refractory chronic heart failure?.Int J Cardiol2017;228:191-7

[29] Geis NA,Bekeredjian R,Kreusser MM.Haemodynamic effects of percutaneous mitral valve edge-to-edge repair in patients with end-stage heart failure awaiting heart transplantation..ESC Hear Fail2018;5:892-901 PMCID:PMC6165942

[30] Crimi G,Ghio S,Magrini G.MitraClip procedure as ‘bridge to list’, the ultimate therapeutic option for end-stage heart failure patients not eligible for heart transplantation due to severe pulmonary hypertension..Pulm Circ2018;8:2045894018791871 PMCID:PMC6240973

[31] Godino C,Agricola E,Chiarito M.Young patient with advanced heart failure no longer a candidate for heart transplantation after MitraClip^® procedure..J Heart Valve Dis2017;26:234-6

[32] Godino C, Munafò A, Scotti A, Estévez-Loureiro R, Portolés Hernández A, et al. Transcatheter mitral valve repair with MitraClip as bridge therapy for heart transplantation: one-year outcome from the international MitraBridge registry. EuroPCR - Late Breaking Trials 2019. Available from: https://media.pcronline.com/diapos/EuroPCR2019/3333-20190521_1600_Room_342A_Godino_Cosmo_1111_(7448)/Godino_Cosmo_20190521_1530_Room_342A.pdf [Last accessed on 13 Jul 2020]